Glypican-3 (GPC3) is associated with MCPyV-negative status and impaired outcome in Merkel cell carcinoma

Introduction: Merkel cell carcinoma (MCC) is an aggressive skin cancer, related to the Merkel Cell Polyomavirus (MCPyV) in 80% of cases. Immune checkpoint inhibitors provide sustained benefit in about 50% of MCC patients with advanced disease. Glypican-3 (GPC3) is an oncofetal tumor antigen that is...

Descripción completa

Detalles Bibliográficos
Autores principales: Muralidharan, Sujatha, Kervarrec, Thibault, Weiss, Glen J., Samimi, Mahtab
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9348696/
https://www.ncbi.nlm.nih.gov/pubmed/35937502
http://dx.doi.org/10.18632/oncotarget.28260

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9348696/
https://www.ncbi.nlm.nih.gov/pubmed/35937502
http://dx.doi.org/10.18632/oncotarget.28260

Ejemplares similares